Cite
HARVARD Citation
Mato, A. et al. (n.d.). PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION. Hematological oncology. pp. 119-120. [Online].